Download full-text PDF |
Source |
|---|---|
| http://dx.doi.org/10.3305/nh.2015.32.sup2.10261 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Enhanced Antitumor Efficacy and Reduced Toxicity in Colorectal Cancer Using a Novel Multifunctional Rg3- Targeting Nanosystem Encapsulated with Oxaliplatin and Calcium Peroxide.
Int J Nanomedicine
January 2025
Department of Biopharmacy, School of Pharmaceutical Sciences, Jilin University, Changchun, People's Republic of China.
Purpose: Colorectal cancer (CRC) is the second leading cause of cancer-related deaths worldwide. Oxaliplatin (OXA) is currently the primary chemotherapeutic agent for CRC, but its efficacy is limited by the tumor microenvironment (TME). Here, we present a combined approach of chemotherapy and TME modulation for CRC treatment.
View Article and Find Full Text PDFHeat-health messaging in Canada: A review and content analysis of public health authority webpages and resources.
Public Health Pract (Oxf)
June 2025
Human and Environmental Physiology Research Unit, School of Human Kinetics, University of Ottawa, Ottawa, ON, Canada.
Background: With the growing threat posed by extreme heat, heat-health messaging communicated by public health authorities is critical for raising community awareness and action. This study sought to (i) identify what heat-health content is shared online by Canadian public health authorities and (ii) analyse the material to develop an understanding of the content included within the resources.
Study Design: Qualitative content analysis.
Practical management of adverse events in patients receiving tarlatamab, a delta-like ligand 3-targeted bispecific T-cell engager immunotherapy, for previously treated small cell lung cancer.
Cancer
February 2025
University of Maryland Marlene and Stewart Greenebaum Comprehensive Cancer Center, University of Maryland Medical Center, Baltimore, Maryland, USA.
Tarlatamab is a bispecific T-cell engager immunotherapy targeting delta-like ligand 3 (DLL3) and the cluster of differentiation 3 (CD3) molecule. In the phase 2 DeLLphi-301 trial of tarlatamab for patients with previously treated small cell lung cancer, tarlatamab 10 mg every 2 weeks achieved durable responses and encouraging survival outcomes. Analyses of updated safety data from the DeLLphi-301 trial demonstrated that the most common treatment-emergent adverse events were cytokine release syndrome (53%), pyrexia (38%), decreased appetite (36%), dysgeusia (32%), and an emia (30%).
View Article and Find Full Text PDFRedox regulation of TRIM28 facilitates neuronal ferroptosis by promoting SUMOylation and inhibiting OPTN-selective autophagic degradation of ACSL4.
Cell Death Differ
January 2025
Translational Research Centre of Orthopedics, Shanghai General Hospital, Shanghai Jiao Tong University School of Medicine, Shanghai, 200080, China.
Ferroptosis is one of the cell death programs occurring after spinal cord injury (SCI) and is driven by iron-dependent phospholipid peroxidation. However, little is known about its underlying regulation mechanism. The present study demonstrated that lipid peroxidation was promoted in patients with SCI.
View Article and Find Full Text PDFInfluence of elevated temperature exposure on the residual compressive strength and radiation shielding efficiency of ordinary concrete incorporating granodiorite and ceramic powders.
Sci Rep
January 2025
Physics Department, Faculty of Science, Fayoum University, Fayoum, Egypt.
This research investigates the potential of utilizing types of construction waste as partial cement replacements within concrete formulations. Notably, granodiorite and ceramic powders were introduced at varying substitution ratios. The impact of these waste materials on the compressive strength and radiation shielding effectiveness of traditional concrete was evaluated under both ambient and elevated temperature conditions.
View Article and Find Full Text PDFWant AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!